{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:48Z","timestamp":1794255888581,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03761-7","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:04:49Z","timestamp":1788005089000},"page":"5714-5726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mummert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-984X","authenticated-orcid":false,"given":"Stella","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7612-9132","authenticated-orcid":false,"given":"Mark","family":"Levenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1364-0915","authenticated-orcid":false,"given":"Griffith","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-2687","authenticated-orcid":false,"given":"Amie","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8547-6624","authenticated-orcid":false,"given":"Melissa","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"2","key":"3761_CR1","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"3761_CR2","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/jdv.20639","volume":"39","author":"A Wollenberg","year":"2025","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: living update. J Eur Acad Dermatol Venereol. 2025;39(9):1537\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3761_CR3","unstructured":"US Food and Drug Administration. Cibinqo (abrocitinib). Prescribing information. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/213871s005lbl.pdf. Accessed July 27, 2026."},{"issue":"12","key":"3761_CR4","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"3761_CR5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"3761_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"3761_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"3","key":"3761_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jaad.2025.11.021","volume":"94","author":"G Yosipovitch","year":"2025","unstructured":"Yosipovitch G, Zirwas M, Rasouliyan L, et al. Combined impact of lesion and itch severity on initiation of biologic treatment in patients with moderate or severe atopic dermatitis from specialty dermatology facilities in the United States. J Am Acad Dermatol. 2025;94(3):979\u201382.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3761_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s13555-025-01590-0","volume":"16","author":"M Zirwas","year":"2025","unstructured":"Zirwas M, Lio P, Rasouliyan L, et al. Healthcare resource utilization and economic burden across clinical phenotypes of moderate-to-severe atopic dermatitis in United States dermatology facilities. Dermatol Ther. 2025;16(1):437\u201350.","journal-title":"Dermatol Ther"},{"issue":"11","key":"3761_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039928","volume":"10","author":"K Abuabara","year":"2020","unstructured":"Abuabara K, Silverberg JI, Simpson EL, et al. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open. 2020;10(11):e039928.","journal-title":"BMJ Open"},{"issue":"1","key":"3761_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12895-018-0072-2","volume":"18","author":"AW Armstrong","year":"2018","unstructured":"Armstrong AW, Foster SA, Comer BS, et al. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. BMC Dermatol. 2018;18(1):4.","journal-title":"BMC Dermatol"},{"issue":"10","key":"3761_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70020","volume":"33","author":"J Li","year":"2024","unstructured":"Li J, Baker R, Stovall R, et al. Agreement of medication information derived from EHR data compared to Medicare insurance claims: an analysis of biologic disease-modifying antirheumatic drugs. Pharmacoepidemiol Drug Saf. 2024;33(10):e70020.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"3761_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/aje\/kwae226","volume":"194","author":"S Schneeweiss","year":"2025","unstructured":"Schneeweiss S, Desai RJ, Ball R. A future of data-rich pharmacoepidemiology studies: transitioning to large-scale linked electronic health record\u00a0+\u00a0claims data. Am J Epidemiol. 2025;194(2):315\u201321.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"3761_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"3761_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","volume":"74","author":"M Futamura","year":"2016","unstructured":"Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288\u201394.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3761_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3761_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26\u201330.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"3761_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00403-021-02282-3","volume":"314","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Begolka WS, Thibau IJ, Silverberg JI. Financial burden and impact of atopic dermatitis out-of-pocket healthcare expenses among Black individuals in the United States. Arch Dermatol Res. 2022;314(8):739\u201347.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"3761_CR19","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1111\/jdv.16876","volume":"34","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Girolomoni G. Undertreatment in adult patients with moderate-to-severe atopic dermatitis and other chronic inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2020;34(10):2168\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3761_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.36849\/JDD.7071","volume":"22","author":"P Lio","year":"2023","unstructured":"Lio P, Mackie D, Bates D, et al. Burden, control, and treatment of moderate to severe atopic dermatitis in 2021: a United States patient survey study. J Drugs Dermatol. 2023;22(2):119\u201331.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"3761_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13555-021-00488-x","volume":"11","author":"AW Vilsb\u00f8ll","year":"2021","unstructured":"Vilsb\u00f8ll AW, Anderson P, Piercy J, Milligan G, Kragh N. Extent and impact of inadequate disease control in US adults with a history of moderate to severe atopic dermatitis following introduction of new treatments. Dermatol Therapy. 2021;11(2):475\u201386.","journal-title":"Dermatol Therapy"},{"key":"3761_CR22","unstructured":"European Medicines Agency. Cibinqo (abrocitinib). Summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf. Accessed July 27, 2026."},{"key":"3761_CR23","doi-asserted-by":"crossref","unstructured":"Chovatiya R, Zirwas M, Gooderham MJ, et al. P2845 Efficacy of abrocitinib flexible dose escalation and reduction versus consistent dosing in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from the Real-World-Simulating Expanded Access Protocol Study, JADE REAL. Poster presented at the European Academy of Dermatology & Venereology Conference; September 17\u201320, 2025; Paris, France.","DOI":"10.25251\/t4rkzz84"},{"key":"3761_CR24","doi-asserted-by":"crossref","unstructured":"Chovatiya R, Zirwas M, Simpson EL, et al. Flexible dosing of abrocitinib in patients with moderate-to-severe atopic dermatitis: initial results from the Real-World-Simulating Expanded Access Protocol Study, JADE REAL. Presented at the Revolutionizing Atopic Dermatitis (RAD) Conference; June 6\u20137, 2025; Nashville, Tennessee.","DOI":"10.25251\/t4rkzz84"},{"key":"3761_CR25","doi-asserted-by":"publisher","first-page":"adv43464","DOI":"10.2340\/actadv.v105.43464","volume":"105","author":"PO Jonsson","year":"2025","unstructured":"Jonsson PO, Tayefi M, Svedbom A, Bradley M, Johansson EK. Drug survival and predictors of systemic treatment outcome in atopic dermatitis: data from a nationwide Swedish cohort. Acta Derm Venereol. 2025;105:adv43464.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"3761_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s12325-024-03052-z","volume":"42","author":"M Rossi","year":"2025","unstructured":"Rossi M, Ferrucci SM, Calzavara-Pinton P, et al. Drug survival, retention, and persistence of dupilumab in adults and adolescents with atopic dermatitis: a narrative literature review. Adv Ther. 2025;42(1):94\u2013105.","journal-title":"Adv Ther"},{"key":"3761_CR27","doi-asserted-by":"publisher","first-page":"adv41504","DOI":"10.2340\/actadv.v105.41504","volume":"105","author":"AR Schlosser","year":"2025","unstructured":"Schlosser AR, Nijman L, Schappin R, Nijsten TEC, Hijnen D. Long-term outcomes of new systemic agents in atopic dermatitis: drug survival analyses and treatment patterns in daily practice. Acta Derm Venereol. 2025;105:adv41504.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"3761_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00403-025-03892-x","volume":"317","author":"MT Polaskey","year":"2025","unstructured":"Polaskey MT, Chovatiya R. Describing atopic dermatitis in real-world clinical practice: a retrospective health system analysis. Arch Dermatol Res. 2025;317(1):365.","journal-title":"Arch Dermatol Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03761-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03761-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:26Z","timestamp":1794254606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03761-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3761"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03761-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Raj Chovatiya has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Argenx, Astria Therapeutics, Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, CLn Skin Care, Dermavant, DKSH, Eli Lilly and Company, EMD Serono, Formation Bio, Forte Biosciences, Galderma, Genentech, GSK, Incyte, Imagene Bio Inc., Johnson & Johnson, Kenvue, Kowa Pharmaceuticals America, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Nia Health, Novartis, Opsidio, Organon, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, SUN Pharma, Takeda, TRex Bio, UCB, Zai Lab, and Zuellig Pharma. Amanda Mummert and Stella Chang are employees of OMNY Health, paid consultants to Pfizer Inc. in connection with this study. Mark Levenberg, Griffith Bell, Amie Scott, and Melissa Watkins are employees and stockholders of Pfizer Inc.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board waiver of approval was obtained from Sterling Institutional Review Board, Atlanta, GA, USA. Patient informed consent was not required because the study utilized only de-identified patient data, which are considered exempt from the requirements for human participant research in the US pursuant to 45 CFR \u00a7 164.514(b)(1).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}